| pubmed-article:16980601 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0679729 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0538927 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:16980601 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16980601 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:16980601 | pubmed:dateCreated | 2006-12-7 | lld:pubmed |
| pubmed-article:16980601 | pubmed:abstractText | There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors. Expression of COX-2 is seen in 93% of melanomas, as determined by immunohistochemistry. Temozolomide (TMZ) has demonstrated activity against melanoma and has been investigated as single agent or in combination. We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib (a COX-2 inhibitor) in patients with advanced melanoma. | lld:pubmed |
| pubmed-article:16980601 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16980601 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16980601 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16980601 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16980601 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:PapadopoulosO... | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:MiddletonMM | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:VaiopoulosGG | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:PectasidesDD | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:FountzilasGG | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:PolyzosAA | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:TsoutsosDD | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:MarkopoulosCC | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:GogasHH | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:MantzouraniMM | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:FrangiaKK | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:PanagiotouPP | lld:pubmed |
| pubmed-article:16980601 | pubmed:author | pubmed-author:StavrinidisII | lld:pubmed |
| pubmed-article:16980601 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16980601 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:16980601 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16980601 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16980601 | pubmed:pagination | 1835-41 | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:meshHeading | pubmed-meshheading:16980601... | lld:pubmed |
| pubmed-article:16980601 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16980601 | pubmed:articleTitle | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. | lld:pubmed |
| pubmed-article:16980601 | pubmed:affiliation | First Department of Medicine, University of Athens, Medical School, Athens, Greece. hgogas@hol.gr | lld:pubmed |
| pubmed-article:16980601 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16980601 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16980601 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16980601 | lld:pubmed |
